doses
treatment of acute malaria infections
side effects
mefloquine
active ingredient
lariam
side effects
disease
common side effects
treatment
dizziness
myalgia
nausea
fever
headache
vomiting
chills
diarrhea
skin rash
abdominal pain
fatigue
loss of appetite
tinnitus
common side effects
malaria prophylaxis
vomiting
long half-life of mefloquine
side effects
several weeks after drug discontinuation
psychiatric side effects
emotional problems
transient emotional disturbances
behavioral changes
vivid dreams
mania
nightmares
delusions
tension
anger
organic psychosis
dysphoria
disorders
abnormal dreams
anxiety
depression
mood swings
panic attacks
aggression
paranoid reactions
suicidal ideation
suicide
postmarketing experience
gastrointestinal side effects
vomiting
nausea
diarrhea
abdominal pain
loss of appetite
mouth ulcers
anorexia
nausea
vomiting
abdominal pain
loose stools
diarrhea
dyspepsia
loss of appetite
postmarketing experience
nervous system
side effects
dizziness
syncope
headache
tinnitus
seizures
encephalopathy of unknown etiology
prophylactic mefloquine
active ingredient
lariam
administration
relationship
drug administration
weakness
myoclonus
dizziness
vertigo
headache
loss of balance
somnolence
sleep disorders
insomnia
motor neuropathies
including paresthesia
tremor
ataxia
convulsions
agitation
restlessness
memory impairment
confusion
hallucinations
encephalopathy
vestibular disorders
including tinnitus
hearing impairment
postmarketing experience
cardiovascular
side effects
extrasystoles
bradycardia
cardiopulmonary arrest
patient after a single prophylactic dose
using propranolol
silent electrocardiograph alterations
including sinus bradycardia
sinus arrhythmia
first degree
atrioventricular block
prolongation of the qtc interval
abnormal t waves
atrial flutter
circulatory disturbances
hypotension
hypertension
flushing
syncope
chest pain
tachycardia
palpitation
bradycardia
irregular heart rate
extrasystoles
atrioventricular block
other transient cardiac conduction alterations
postmarketing experience
year-old male experienced thrombotic thrombocytopenic purpura
ttp
mefloquine
active ingredient
lariam
therapy
week before admission
patient
weakness
days
anorexia
myalgia
lethargy
fever
confusion
vision
central venous catheter
right jugular vein
plasmapheresis sessions
units of fresh frozen plasma
first hours
neurological status
first plasmapheresis
hematological abnormalities
first few days of therapy
patient
presence of severe neurological symptoms
fever
thrombocytopenia
microangiopathic anemia
complex hematological abnormality
ttp
causal relation between drug
disease
temporal relation of drug intake with the onset of the clinical symptoms
laboratory abnormalities
prompt improvement after the aphaeretic therapy
drug withdrawal
hematologic side effects
decreased hematocrit
leukopenia
leukocytosis
thrombocytopenia
anemia
least cases
isolated thrombocytopenia
cases of hemolytic anemia
case of thrombotic thrombocytopenic purpura
agranulocytosis
aplastic anemia
postmarketing experience
dermatologic side effects
skin rash
hair loss
pruritus
telogen effluvium
itching
cutaneous vasculitis
rash
exanthema
erythema
urticaria
pruritus
hair loss
hyperhidrosis
erythema multiforme
stevens-johnson syndrome
postmarketing experience
other side effects
asthenia
fatigue
fever
chills
asthenia
edema
malaise
fatigue
fever
chills
postmarketing experience
musculoskeletal side effects
myalgia
severe arthralgias
myalgias
muscle weakness
muscle cramps
myalgia
arthralgia
postmarketing experience
hypersensitivity side effects
hypersensitivity reactions
mild cutaneous events
anaphylaxis
respiratory side effects
dyspnea
pneumonitis of possible allergic etiology
postmarketing experience
case of eosinophilic pneumonia
history of pityriasis versicolor
eosinophilic pneumonia
infliximab therapy
experienced high-grade fever
degrees celsius
malaise
productive cough
dyspnea on exertion during the previous week
south africa for weeks
taken oral mefloquine mg
week as malaria prophylaxis
therapy
weeks
home
thorough workup
diagnosis of eosinophilic pneumonia
mefloquine therapy
condition
drug
hepatic side effects
transient elevation of transaminases
drug-related hepatic disorders from asymptomatic transient transaminase elevations
hepatic failure
postmarketing experience
ocular side effects
visual disturbances
postmarketing experience
aching joints
muscles
anxiety
blistering
loosening
peeling
redness of the skin
chest pain
discomfort
chills
confusion
convulsions (seizures)
cough or hoarseness
dizziness
fainting
fever
hallucinations
seeing
hearing
feeling things
pounding
heartbeat
pulse
irritability
lightheadedness
side pain
mental depression
difficult urination
red spots on the skin
irritated eye
restlessness
sore throat
sores
ulcers
white spots in the mouth
lips
stiff neck
swelling of the ankles
feet
lower legs
unusual bleeding
bruising
unusual tiredness
weakness
vomiting
loss of vision
continuing ringing
buzzing
other unexplained noise in the ears
disturbed color perception
double vision
feeling of constant movement of self
surroundings
halos around lights
hearing loss
hearing problems
loss of balance
loss of bladder control
muscle spasm
jerking of all extremities
night blindness
overbright appearance of lights
sensation of spinning
continuing headache
sudden loss of consciousness
trouble sleeping
troubled breathing
tunnel vision
diarrhea
emotional problems
nausea
stomach pain
abnormal dreams
loss of appetite
skin rash
loss of hair
acid
sour stomach
belching
flushing
redness of the skin
heartburn
indigestion
skin rash with a general disease
stomach discomfort
pain
swelling
unusually warm skin